Ingenia Therapeutics인제니아테라퓨틱스(Reg.S)

Ingenia Therapeutics, listed in August 2026, has no reported revenue or profit in the data and trades well below its 52-week high.

Ingenia Therapeutics is a Korean biotech that listed on KOSDAQ on 2026-08-18 and closed at ₩23,250 on 2026-10-27, for a market value of about ₩1.15T. The data includes no revenue, operating income, net income or free cash flow for the trailing period, and no company profile or news headlines were provided. The most recent filing is a major management matter dated 2026-10-27.

What stands out

• Shares closed at ₩23,250, about 22% below the 52-week high of ₩29,950 and well above the 52-week low of ₩9,900; the 1-month return was -4.7%.
• Trailing profit and revenue figures are not available in the data, so the earnings picture cannot be assessed.
• Cash was reported at about ₩4.9B, and liabilities equal 66.9% of equity.
• Price-to-book is shown at about 116,558x, which is not meaningful for judging value; price-to-earnings and other multiples are not available.
• Over the last 20 days, retail investors were net buyers (about ₩9.1B), while foreign and institutional investors were net sellers; foreign ownership is 1.3%.

What to watch

• Upcoming filings, including the 2026-10-27 major management matter, which the data does not describe.
• Whether the company begins to report revenue and earnings, since the data currently shows none.
• Insider and 5%+ holder reporting activity following the listing, which could signal changes in share ownership.